Did Tenon Medical beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Tenon Medical year over year?

What were the key takeaways from Tenon Medical’s earnings call?

What does Tenon Medical do and what are its main business segments?

What is Tenon Medical's gross profit margin?

What guidance did Tenon Medical's management provide for the next earnings period?

What is the market's earnings forecast for Tenon Medical next quarter?

What is Tenon Medical's latest dividend and current dividend yield?

- **Revenue Surge**: 32% YoY growth to $1.2 million, fueled by Catamaran and SiVantage integration.
- **Clinical Validation**: 83% fusion rate and significant pain reduction validate Catamaran efficacy.
- **Strategic Expansion**: SImmetry+ alpha launch and hybrid sales model position for lateral approach dominance.
- **Financial Resilience**: $3.4 million cash post-PIPE, supporting aggressive growth without debt.

**【CEO Summary Section】**
- **Record Revenue Growth**: Q3 2025 revenue reached $1.2 million, a 32% year-over-year increase, driven by Catamaran procedure volumes and the SiVantage acquisition.
- **Product Launches**: Full launch of Catamaran SE with enhanced design for smaller SI joints; FDA clearance for SImmetry+ with alpha launch commencing.
- **Clinical Success**: Peer-reviewed study showed 83% fusion rate at 12 months, with significant pain reduction (VAS 78.8 to 23.0) and satisfaction rates.
- **Integration Progress**: Seamless integration of SiVantage assets, with key leadership onboarding and shared clinical principles.
- **Financial Health**: $3.4 million cash post-PIPE financing, supporting strategic initiatives.

**【CFO Commentary】**
- **Revenue Breakdown**: $1.1 million from Catamaran, $0.1 million from SiVantage; gross profit $0.8 million (66% margin), up from $0.4 million (47% margin) in Q3 2024.
- **Operating Expenses**: $4.2 million (32% YoY increase) due to acquisition-related costs; 9-month operating expenses down 6% to $11.3 million.
- **Net Loss**: $3.3 million, improved from $3.6 million in Q3 2024, with reduced fixed costs.
- **Liquidity**: $3.4 million cash, bolstered by $2.85 million PIPE for growth.

**【Q&A Highlights】**
- **Growth Expectations**: Sequential Catamaran growth in Q4, with SImmetry+ alpha launch contributing modestly.
- **Launch Strategy**: Focused alpha phase for SImmetry+ to gather feedback before broader rollout.
- **Sales Model**: Hybrid approach with trained distributors and direct sales, emphasizing multi-product expertise.
- **Payer Coverage**: Ongoing efforts to leverage clinical data for expanded coverage, prioritizing prospective studies.

Tenon Medical, Inc. (TNON) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

TNON

TNON fundamentals

You can ask Aime